(IZAFE-B) iZafe Series - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0003656834
IZAFE-B: Medical Dispensers, Digital Services, Drug Management Systems
iZafe Group AB (publ), a Swedish medical technology company, specializes in developing and marketing digital health solutions aimed at improving medication adherence and safety. The companys product portfolio includes Dosell, an automated medication dispenser designed to simplify drug management for patients, and Pilloxa, a digital platform that provides real-time monitoring and data-driven insights to enhance patient engagement and adherence. iZafe Group AB (publ) was established in 2008 and is headquartered in Stockholm, Sweden. The company rebranded from MediRätt AB (publ) to iZafe Group AB (publ) in May 2019, reflecting its expanded focus on innovative digital health solutions. Web URL: https://www.izafe.se
ticker Symbol: IZAFE-B exchange: ST type: common stock country Origin: Sweden gics Sub Industry: Life Sciences Tools & Services
Based on the provided
Additional Sources for IZAFE-B Stock
IZAFE-B Stock Overview
Market Cap in USD | 8m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception |
IZAFE-B Stock Ratings
Growth 5y | -70.1% |
Fundamental | 2.38% |
Dividend | 0.0% |
Rel. Strength Industry | 7.45 |
Analysts | - |
Fair Price Momentum | 0.20 SEK |
Fair Price DCF | - |
IZAFE-B Dividends
No Dividends PaidIZAFE-B Growth Ratios
Growth Correlation 3m | 87% |
Growth Correlation 12m | 3.2% |
Growth Correlation 5y | -91.7% |
CAGR 5y | -30.30% |
CAGR/Max DD 5y | -0.32 |
Sharpe Ratio 12m | -0.07 |
Alpha | -2.83 |
Beta | 0.87 |
Volatility | 73.43% |
Current Volume | 141.3k |
Average Volume 20d | 217.9k |
As of March 16, 2025, the stock is trading at SEK 0.26 with a total of 141,333 shares traded.
Over the past week, the price has changed by -0.77%, over one month by +8.40%, over three months by +18.35% and over the past year by +8.40%.
Neither. Based on ValueRay Fundamental Analyses, iZafe Series is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IZAFE-B as of March 2025 is 0.20. This means that IZAFE-B is currently overvalued and has a potential downside of -23.08%.
iZafe Series has no consensus analysts rating.
According to ValueRays Forecast Model, IZAFE-B iZafe Series will be worth about 0.2 in March 2026. The stock is currently trading at 0.26. This means that the stock has a potential downside of -15.38%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 0.3 | 15.4% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.2 | -15.4% |